Clinical Overview
Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer orally using the calibrated measuring syringe or cup provided. Can be mixed in a glass of water. Take twice daily at 12-hour intervals, with or without meals.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Somnolence, asthenia, fatigue, dizziness, nasopharyngitis, headache. Rare/Severe: Behavioral and psychiatric symptoms (irritability, aggression, depression, emotional lability, psychosis, suicidality), severe hypersensitivity reactions (DRESS, SJS), and pancytopenia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Monitor closely for behavioral disturbances, aggression, and emergence of suicidal thoughts. Dose adjustment is required according to creatinine clearance in patients with renal impairment. Complete the full prescribed course.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Levetiracetam Tablets 500 mg
Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.
Levetiracetam Tablets 1000 mg
Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.
Levetiracetam Tablets 250 mg
Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.
Levetiracetam Tablets 750 mg
Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.